Patent ID: 8507442

Claim:
A method of inhibiting tumor growth in a subject, comprising administering to the subject a therapeutically effective amount of an antibody that specifically binds at least one human frizzled receptor (FZD) selected from the group consisting of FZD1, FZD2, FZD5, FZD7 and FZD8, wherein the antibody is selected from the group consisting of: a) an antibody comprising: (i) a heavy chain CDR1 comprising GFTFSHYTLS (SEQ ID NO:1), a heavy chain CDR2 comprising VISGDGSYTYYADSVKG (SEQ ID NO:2), and a heavy chain CDR3 comprising NFIKYVFAN (SEQ ID NO:3), and (ii) a light chain CDR1 comprising SGDKLGKKYAS (SEQ ID NO:4) or SGDNIGSFYVH (SEQ ID NO:7), a light chain CDR2 comprising EKDNRPSG (SEQ ID NO:5) or DKSNRPSG (SEQ ID NO:8), and a light chain CDR3 comprising SSFAGNSLE (SEQ ID NO:6) or QSYANTLSL (SEQ ID NO:9); (b) an antibody comprising: (i) a heavy chain variable region having the amino acid sequence of SEQ ID NO:10; and (ii) a light chain variable region having the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:14; (c) an antibody encoded by the sequence of a plasmid deposited with the ATCC as accession number PTA-9540 or PTA-9541; and (d) an antibody that competes for specific binding to the at least one human frizzled receptor with a second antibody, wherein the second antibody comprises a heavy chain variable region comprising SEQ ID NO:10 and a light chain variable region comprising SEQ ID NO:14.